

## IMPAACT Protocols Snapshot: In Development through Closed to Follow Up

Protocol #	Title	Sites	Study Status	Research Area	Protocol to Sites (Projected)	Open to Accrual (Projected)	1st Participant Enrolled (Projected)	Closed to Accrual (Projected)	Closed to Follow Up (Projected)	Target Accrual	Actual Accrual as of report date
<b>IMPAACT 2036</b>	Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV ≥2 to <12 years of age	TBD	In Development	Treatment	30-Jun-22	30-Sep-22	30-Dec-22	TBD	TBD	60	NA
<b>IMPAACT 2035/ HVTN 604</b>	Phase I/II Study of the Safety and Immunogenicity of VPM1002 Vaccination and BCG Re-Vaccination against Tuberculosis in South African Pre-Adolescents Living with and without HIV	TBD	In Development	Tuberculosis	Q1 2022	31-May-22	31-Jul-22	31-Jul-24	31-Jul-25	480	NA
<b>IMPAACT 2034</b>	Phase I Study of the Pharmacokinetics, Safety, and Acceptability of Pretomanid in Children with Rifampicin-Resistant Tuberculosis	TBD	In Development	Tuberculosis	20-Dec-21	20-Mar-22	18-Jun-22	17-Dec-23	31-Dec-23	TBD	NA
<b>IMPAACT 2029</b>	Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV	US	In Development	Treatment	14-Aug-21	15-Oct-21	15-Nov-21	15-Nov-22	15-May-24	12	NA
<b>IMPAACT 2025</b>	Safety, Tolerability, and Pharmacokinetics of One Month of Daily versus Three Months of Weekly Isoniazid and Rifapentine in HIV-Infected Pregnant and Postpartum Women	TBD	In Development	Tuberculosis	TBD	TBD	TBD	TBD	TBD	TBD	NA
<b>IMPAACT 2024</b>	Phase I/II Dose Finding and Safety Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents	TBD	In Development	Tuberculosis	TBD	TBD	TBD	TBD	TBD	TBD	NA
<b>IMPAACT 2023</b>	A Phase I Trial of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1	US/INTL	In Development	Treatment	16-Jul-21	31-Aug-21	30-Sep-21	30-Sep-23	31-Jan-24	108	NA
<b>IMPAACT 2022</b>	Phase II Study of the Virologic Efficacy and Feasibility of Long Acting Injectable Antiretroviral Medications in Non-Adherent Youth with HIV	TBD	In Development	Treatment	TBD	TBD	TBD	TBD	TBD	70	NA
<b>IMPAACT 2020</b>	A Phase II Study of Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Children (SMaRT Kids)	INTL	In Development	Tuberculosis	TBD	TBD	TBD	TBD	TBD	169 children and 169 caregivers	NA
<b>IMPAACT 2028</b>	Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV Infection	US/INTL	Pending	Cure	31-Dec-20	12-Jul-21	25-Aug-21	30-Nov-26	30-Nov-27	250	NA
<b>IMPAACT 2026</b>	Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum	US/INTL	Open to Accrual	Treatment	04-Feb-20	08-Jun-21	01-Sep-21	30-Apr-26	01-Aug-26	325	0
<b>IMPAACT 2016</b>	Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings	INTL	Open to Accrual	Complications	08-Nov-18	27-Nov-19	TBD	TBD	TBD	256	0
<b>IMPAACT 2032</b>	Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States	US	Enrolling	COVID-19	03-Aug-20	12-Feb-21	31-Mar-21	01-Sep-21	01-Sep-22	40	18

TBD = information is to be added once timeline is clearer  
 Grey text boxes indicates a projected (rather than actual) date

Based on data available through 29 June 2021  
 Page 1 of 3

## IMPAACT Protocols Snapshot: In Development through Closed to Follow Up

Protocol #	Title	Sites	Study Status	Research Area	Protocol to Sites (Projected)	Open to Accrual (Projected)	1st Participant Enrolled (Projected)	Closed to Accrual (Projected)	Closed to Follow Up (Projected)	Target Accrual	Actual Accrual as of report date
<b>IMPAACT 2019</b>	Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age	US/INTL	Enrolling	Treatment	08-Oct-18	20-Jul-20	09-Sep-20	09-Sep-21	09-Sep-24	75	57
<b>IMPAACT 2021</b>	Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/11314L, RSV 6120/ΔNS2/1030s, or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age	US	Enrolling	Complications	28-Mar-19	16-May-19	20-Jun-19	14-Oct-22	30-Apr-23	160	30
<b>IMPAACT 2003b/A5300b</b>	Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients (PHOENIX MDR-TB)	INTL	Enrolling	Tuberculosis	2-Oct-18 (V2)	03-Jun-19	13-Jun-19	20-Oct-23	20-Oct-25	3452 (household); 1726 (index)	597 (household); 383 (index)
<b>IMPAACT 2017</b>	Phase I/II Study of Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents: MOCHA (More Options for Children and Adolescents)	US/INTL	Enrolling	Treatment	16-Mar-18	19-Mar-19	03-Apr-19	31-Jul-22	31-Jul-25	155	33
<b>IMPAACT 2009</b>	Pharmacokinetics, Feasibility, Acceptability, & Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy & Postpartum in Adolescents & Young Women & their Infants	INTL	Enrolling	Prevention	02-Nov-17	09-Jul-18	04-Mar-19	31-Aug-22	31-Aug-23	390	40 pairs
<b>IMPAACT 2005</b>	A Phase I/II Open-label, Single-Arm Study to Evaluate the PK, Safety, & Tolerability of Delamanid in Combination with OBR for MDR-TB in HIV-infected & HIV-uninfected Children with MDR-TB	INTL	Enrolling	Tuberculosis	21-Mar-17	30-Jan-18	18-Feb-19	31-Jul-23	02-Jun-25	48	4
<b>P1108</b>	Phase I/II, Open-Label, Single Arm Study to Evaluate the PK, Safety & Tolerability of Bedaquiline in Combination with Optimized Individualized MDR-TB Therapy in HIV-Infected & HIV-Uninfected Infants, Children & Adolescents with MDR-TB Disease	INTL	Enrolling	Tuberculosis	09-Mar-16	18-Aug-17	21-Sep-17	30-Sep-22	30-Sep-24	72	32
<b>P1115</b>	Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study	US/INTL	Enrolling	Cure	20-Mar-14	24-Jun-14	23-Jan-15	31-Dec-23	30-Dec-32	905 pairs	557 pairs
<b>P1107</b>	Cord Blood Transplantation with CCR5Δ32 Donor Cells in HIV-1 Infected Subjects who Require Bone Marrow Transplantation for any Indication and Its Observed Effects on HIV-1 Persistence	US	Closed to Accrual	Cure	08-Aug-13	04-Mar-14	05-Feb-15	12-Oct-20	31-Oct-21	25	2
<b>P1112</b>	Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants	US/INTL	Closed to Accrual	Prevention	22-Aug-14	21-Apr-15	30-Jun-15	24-Feb-20	28-Feb-22	79 pairs	83 pairs

TBD = information is to be added once timeline is clearer  
 Grey text boxes indicates a projected (rather than actual) date

Based on data available through 29 June 2021  
 Page 2 of 3

## IMPAACT Protocols Snapshot: In Development through Closed to Follow Up

Protocol #	Title	Sites	Study Status	Research Area	Protocol to Sites (Projected)	Open to Accrual (Projected)	1st Participant Enrolled (Projected)	Closed to Accrual (Projected)	Closed to Follow Up (Projected)	Target Accrual	Actual Accrual as of report date
P1093	Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents	US/INTL	Closed to Accrual	Treatment	21-Dec-10	14-Mar-11	20-Apr-11	19-Feb-20	19-Feb-24	300	181
IMPAACT 2014	Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1 infected Children and Adolescents	US/INTL	Closed to Accrual	Treatment	19-Oct-17	21-Mar-18	02-Jul-18	26-Feb-20	29-Dec-21	65	55
P1102/START	Strategic Timing of Antiretroviral Treatment (START)	US	Closed to Accrual	Treatment	12-Dec-08	20-Jul-11	22-Sep-11	23-Dec-13	31-Dec-21	4685	4561
IMPAACT 2008	Phase I/II Multisite Randomized Controlled Study of Monoclonal Antibody VCR01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants	US/INTL	Closed to Follow-up*	Cure	09-Nov-16	08-May-18	06-Aug-18	11-Mar-20	11-Feb-21	68 pairs	61 infants and 58 mothers
IMPAACT 2010	Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants	US/INTL	POS/PAC*	Treatment	13-Dec-16	12-Dec-17	19-Jan-18	08-Feb-19	02-Feb-21	639	643 pairs
IMPAACT 2018	Randomized Phase I Study of the Infectivity, Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/11314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age	US	POS/PAC*	Complications	03-Jul-17	04-Aug-17	22-Sep-17	14-Oct-19	01-Oct-20	80	65

\* last 8 months

**Research Area:**

**Complications** 2021, 2018, 2016  
**Cure** 2028, 2008, P1115, P1107  
**Prevention** 2009, P1112  
**Treatment** 2036, 2029, 2026, 2023, 2022, 2019, 2017, 2014, 2010, P1102/START, P1093  
**Tuberculosis** 2035/HVTN 604, 2034, 2025, 2024, 2020, 2005, 2003b/A5300b, P1108  
**COVID-19** 2032